Gates Katherine V, Pereira Naveen L, Griffiths Leigh G
Department of Veterinary Medicine and Epidemiology, University of California, Davis, Davis, CA, United States.
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Front Immunol. 2017 Oct 18;8:1332. doi: 10.3389/fimmu.2017.01332. eCollection 2017.
Historically efforts have focused on the human leukocyte antigen (HLA) as the major cause for acute and chronic rejection following cardiac transplantation. However, rising evidence indicates that non-HLA antibodies can be both primary initiators and modifiers of antibody-mediated rejection (AMR) and cardiac allograft vasculopathy (CAV). The purpose of this review is to assess currently available technologies for non-HLA identification and leveraging such responses toward antibody quantification. Several techniques have been used to identify antigenic determinants of recipient graft-specific non-HLA humoral immune responses, but each comes with its own set of benefits and caveats. Improving our ability to detect non-HLA humoral immune response will aid in our understanding of the underlying antigenic determinants of AMR and CAV, as well as improve patient outcomes.
从历史上看,人们一直将重点放在人类白细胞抗原(HLA)上,认为它是心脏移植后急性和慢性排斥反应的主要原因。然而,越来越多的证据表明,非HLA抗体既可以是抗体介导的排斥反应(AMR)和心脏移植血管病变(CAV)的主要引发因素,也可以是其调节因素。本综述的目的是评估目前可用于非HLA鉴定的技术,并利用这些反应进行抗体定量。已经使用了几种技术来鉴定受体移植物特异性非HLA体液免疫反应的抗原决定簇,但每种技术都有其自身的一系列优点和注意事项。提高我们检测非HLA体液免疫反应的能力将有助于我们了解AMR和CAV的潜在抗原决定簇,并改善患者的治疗结果。